BridgeBio Oncology
BBOT
31 hedge funds and large institutions have $167M invested in BridgeBio Oncology in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
7% more funds holding
Funds holding: 29 → 31 (+2)
4.05% more ownership
Funds ownership: 84.98% → 89.02% (+4%)
0% more capital invested
Capital invested by funds: $167M → $167M (+$524K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.83M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$1.49M |
| 3 |
Millennium Management
New York
|
+$119K |
| 4 |
Walleye Capital
New York
|
+$6.59K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$180K |
| 2 |
CAC
Cowen and Company
New York
|
-$40.2K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$35.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MCM
26
Moore Capital Management
New York
| $1.02M | – | – | – |
|
|
27
Walleye Capital
New York
| $949K | +$6.59K | +640 | +0.7% |
|
28
Walleye Trading
New York
| $534K | +$3.71K | +360 | +0.7% |
|
|
CAC
29
Cowen and Company
New York
| $516K | -$40.2K | -3,902 | -7% |
|
30
Geode Capital Management
Boston,
Massachusetts
| $111K | – | – | – |
|
31
JP Morgan Chase
New York
| $41 | – | – | – |
|
BBOT Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q2 2024, worth a combined $167M — up 0.31% from $167M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBOT positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $1.83M. The largest seller was Wellington Management Group, cutting an estimated $180K.
- 31 institutional investors held BridgeBio Oncology (BBOT) as of Q2 2024, up from 29 in Q1 2024.
- Funds reported $167M of BridgeBio Oncology stock for Q2 2024, up 0.31% quarter-over-quarter.
- 2 funds opened new BridgeBio Oncology positions in Q2 2024 and 0 closed out, a net change of +2 holders.
- The largest BridgeBio Oncology buyer in Q2 2024 was Acuta Capital Partners, an estimated $1.83M added.
- The largest BridgeBio Oncology seller in Q2 2024 was Wellington Management Group, an estimated $180K sold.
Based on aggregated 13F filings for Q2 2024.